Még nem toboroz
Edoxaban Versus Apixaban in Cancer-Associated Venous Thromboembolism
NCT07852637· 4. fázis· Samsung Medical Center· Forrás
Contact: Hyukjin Park
Toboroz
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT07518186· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
NCT07393282· 3. fázis· Regeneron Pharmaceuticals· Forrás
Contact: Clinical Trials Administrator
Toboroz
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
NCT07472517· 3. fázis· Boehringer Ingelheim· Forrás
Contact: Boehringer Ingelheim
Toboroz
Belvarafenib in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant Melanoma
NCT07449754· 2. fázis· Hanmi Pharmaceutical Company Limited· Forrás
Contact: Young Su (Bobby) Noh
Toboroz
A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
NCT07222761· 3. fázis· Regeneron Pharmaceuticals· Forrás
Contact: Clinical Trials Administrator
Toboroz
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
NCT07185997· 3. fázis· ArriVent BioPharma, Inc.· Forrás
Contact: Clinical Trials
Toboroz
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
NCT07007312· 3. fázis· Kura Oncology, Inc.· Forrás
Toboroz
mFOLFOX/mFOLFIRI vs. mFOLFOX in Advanced or Recurrent Biliary Tract Cancer Second-line
NCT07062536· 2. fázis· Seoul National University Bundang Hospital· Forrás
Contact: Hyun Jong Kim, MD, PhD
Fut, nem toboroz
P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk
NCT06468033· 3. fázis· PharmaEssentia· Forrás
Toboroz
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
NCT06881784· 3. fázis· Revolution Medicines, Inc.· Forrás
Contact: Revolution Medicines Study Director
Toboroz
Efficacy of Risk-Stratified Treatment in Newly Diagnosed Infant Leukemia
NCT06516679· 2. fázis· Yonsei University· Forrás
Contact: Hee Jo Baek
Toboroz
Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple Myeloma
NCT06645678· 1/2. fázis· YOUNGIL KOH· Forrás
Contact: Youngil Koh, MD, PhD
Fut, nem toboroz
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
NCT06629779· 3. fázis· Pfizer· Forrás
Fut, nem toboroz
A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).
NCT06551324· 3. fázis· Pfizer· Forrás
Toboroz
Treatment of Pediatric Very High-risk Acute Lymphoblastic Leukemia in Korea
NCT06257394· 2. fázis· Hyoung Jin Kang· Forrás
Contact: Hee Jo Baek, Professor
Toboroz
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
NCT06561386· 3. fázis· Bristol-Myers Squibb· Forrás
Contact: Young-Chul Kim, Site 0458
Toboroz
A Study to Evaluate the Long-Term Safety of Idecabtagene Vicleucel Treatment in Adults With Newly Diagnosed Multiple Myeloma in Korea
NCT06698887· Bristol-Myers Squibb· Forrás
Contact: Sung Hoon Jung, Site 0041
Fut, nem toboroz
A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery
NCT06161441· 2. fázis· Regeneron Pharmaceuticals· Forrás
Toboroz
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
NCT06500273· 2. fázis· Allogene Therapeutics· Forrás
Contact: Deok-Hwan Yang, MD (principal investigator)
Toboroz
Evaluation of Treatment Efficacy According to Risk Group in Relapsed Childhood Acute Lymphoblastic Leukemia
NCT05827549· 2. fázis· Ho Joon Im· Forrás
Contact: Hee Jo Baek, Ph.D
Toboroz
Treatment of Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia in Children
NCT06099366· 2. fázis· Hee Young Ju· Forrás
Contact: Hee Jo Baek, Professor
Toboroz
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
NCT06119581· 3. fázis· Eli Lilly and Company· Forrás
Contact: Young-Chul Kim (principal investigator)
Fut, nem toboroz
Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma
NCT05948475· 3. fázis· TransThera Sciences (Nanjing), Inc.· Forrás
Fut, nem toboroz
A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation
NCT06045806· 3. fázis· Celgene· Forrás
Toboroz
A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer
NCT06038578· 2. fázis· Toray Industries, Inc· Forrás
Contact: Principal Investigator
Toboroz
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
NCT05730036· 3. fázis· Regeneron Pharmaceuticals· Forrás
Contact: Clinical Trials Administrator
Toboroz
Anti-PD-1 Antibody Therapies of Camrelizumab in Combination With Pemetrexed and Carboplatin as First-line Treatment in Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
NCT05841472· 2. fázis· CrystalGenomics, Inc.· Forrás
Contact: Injae Oh, M.D.
Fut, nem toboroz
A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)
NCT05557591· 2. fázis· Regeneron Pharmaceuticals· Forrás
Toboroz
Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis- CloPidogREl for Primary preVENTION (HOST-PREVENTION)
NCT05845489· 4. fázis· Seoul National University Hospital· Forrás
Contact: Ju Han kim, MD,PhD
Meghívásos bevonás
G7 Dual Mobility With Vivacit-E or Longevity PMCF
NCT05548972· Zimmer Biomet· Forrás
Toboroz
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
NCT05503797· 2. fázis· Fore Biotherapeutics· Forrás
Contact: Jessica Rine
Toboroz
Platform Study of Circulating Tumor DNA Directed Adjuvant Chemotherapy in Colon Cancer (KCSG CO22-12)
NCT05534087· 3. fázis· Seoul National University Hospital· Forrás
Contact: Sang Hee Cho, M.D.,Ph.D
Fut, nem toboroz
A Study of Daratumumab
NCT05438043· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
NCT05552222· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
NCT05519085· 3. fázis· Celgene· Forrás
Contact: Sung Hoon Jung, Site 0085
Toboroz
Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer
NCT05254171· 2/3. fázis· Panbela Therapeutics, Inc.· Forrás
Contact: Jun Eul Hwang, MD
Toboroz
Therapeutic Effect of Surgical Debulking of Metastatic Lymph Nodes in Cervical Cancer Stage IIICr
NCT05421650· CHA University· Forrás
Contact: Seok Mo Kim (principal investigator)
Toboroz
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
NCT04988555· 1/2. fázis· Sumitomo Pharma America, Inc.· Forrás
Contact: Jae-Sook Ahn, MD
Fut, nem toboroz
A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)
NCT04819100· 3. fázis· Eli Lilly and Company· Forrás
Fut, nem toboroz
Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia
NCT04994717· 3. fázis· Amgen· Forrás
Fut, nem toboroz
Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC
NCT04919811· 2. fázis· Nuvation Bio Inc.· Forrás
Fut, nem toboroz
Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma
NCT04674683· 3. fázis· HUYABIO International, LLC.· Forrás
Fut, nem toboroz
Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)
NCT04704934· 3. fázis· Daiichi Sankyo· Forrás
Toboroz
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
NCT04752722· 1/2. fázis· enGene, Inc.· Forrás
Contact: enGene clinical trials
Fut, nem toboroz
Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis
NCT04562389· 3. fázis· Karyopharm Therapeutics Inc· Forrás
Fut, nem toboroz
Neoadjuvant FOLFOX Chemotherapy for Patients With Locally Advanced Colon Cancer
NCT03426904· 3. fázis· Kyungpook National University Hospital· Forrás
Fut, nem toboroz
A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer
NCT04077099· 1/2. fázis· Regeneron Pharmaceuticals· Forrás
Toboroz
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
NCT04198766· 1/2. fázis· Inhibrx Biosciences, Inc· Forrás
Contact: In-Jae Oh, MD, MS, PhD (principal investigator)
Fut, nem toboroz
Safety and Efficacy of the ANTHEM™ CR Total Knee System
NCT03885622· Smith & Nephew Pte Ltd· Forrás
Showing 50 of 52.